Evidence map›Paper›PMID 36450971›Full record

SynthesisNeurocritical care2023

Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.

Adnan I Qureshi, Iqra N Akhtar, Xiaoyu Ma, Abdullah Lodhi, Ibrahim Bhatti, Jonathan Beall, Joseph P Broderick, Christy N Cassarly, Renee H Martin, Rishi Sharma and 2 more

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Neurocritical care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07249853 (Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07249853 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial

TypeinterventionalSponsorBeijing Tiantan HospitalRan2025 to 2027Enrolled316ConditionsAneurysmal Subarachnoid HemorrhageArmsCilostazol 100 mg BID, placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Adnan I QureshiDepartment of Neurology, University of Missouri, Columbia, MO, USA. qureshai@gmail.com.
Iqra N AkhtarDepartment of Neurology, University of Missouri, Columbia, MO, USA.
Xiaoyu MaDepartment of Neurology, University of Missouri, Columbia, MO, USA.
Abdullah LodhiDepartment of Neurology, University of Missouri, Columbia, MO, USA.
Ibrahim BhattiDepartment of Neurology, University of Missouri, Columbia, MO, USA.
Jonathan BeallDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Joseph P BroderickDepartment of Neurology, University of Cincinnati, Cincinnati, OH, USA.
Christy N CassarlyDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Renee H MartinDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Rishi SharmaDepartment of Neurology, University of Missouri, Columbia, MO, USA.
Mahesh ThakkarDepartment of Neurology, University of Missouri, Columbia, MO, USA.
Jose I SuarezDivision of Neurosciences Critical Care, Departments of Anesthesiology and Critical Care Medicine, Neurology, and Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
University of Missouri · USMedical University of South Carolina · USCentraCare Health System · USJohns Hopkins University · USUniversity of Cincinnati · US

Funding

Neuronal mechanisms mediating the effects of chronic alcohol consumption on sleep homeostasis.R01AA028175 · NIAAA · UNIVERSITY OF MISSOURI-COLUMBIA · PI THAKKAR, MAHESH M · 2019 to 2023
$1.8M
BLRD VA I01 BX006240NIAAA NIH HHS R01 AA028175
6 · The paper itself

Abstract

backgroundCilostazol, a phosphodiesterase III inhibitor, appears to be a promising agent for preventing cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. Here, the authors perform a systematic review and meta-analysis to quantitatively assess the effects of cilostazol on brain structural and functional outcomes in animal models of cerebral ischemia and subarachnoid hemorrhage-induced cerebral vasospasm.

methodsBy using the PRISMA guidelines, a search of the PubMed, Scopus, and Web of Science was conducted to identify relevant studies. Study quality of each included study for both systematic reviews were scored by using an adapted 15-item checklist from the Collaborative Approach to Meta-Analysis of Animal Data from Experimental Studies. We calculated a standardized mean difference as effect size for each comparison. For each outcome, comparisons were combined by using random-effects modeling to account for heterogeneity, with a restricted maximum likelihood estimate of between-study variance.

resultsA total of 22 (median [Q1, Q3] quality score of 7 [5, 8]) and 6 (median [Q1, Q3] quality score of 6 [6, 6]) studies were identified for cerebral ischemia and subarachnoid hemorrhage-induced cerebral vasospasm, respectively. Cilostazol significantly reduced the infarct volume in cerebral ischemia models with a pooled standardized mean difference estimate of - 0.88 (95% confidence interval [CI] [- 1.07 to - 0.70], p < 0.0001). Cilostazol significantly reduced neurofunctional deficits in cerebral ischemia models with a pooled standardized mean difference estimate of - 0.66 (95% CI [- 1.06 to - 0.28], p < 0.0001). Cilostazol significantly improved the basilar artery diameter in subarachnoid hemorrhage-induced cerebral vasospasm with a pooled standardized mean difference estimate of 2.30 (95% CI [0.94 to 3.67], p = 0.001). Cilostazol also significantly improved the basilar artery cross-section area with a pooled standardized mean estimate of 1.88 (95% CI [0.33 to 3.43], p < 0.05). Overall, there was between-study heterogeneity and asymmetry in the funnel plot observed in all comparisons.

conclusionsPublished animal data support the overall efficacy of cilostazol in reducing infarct volume and neurofunctional deficits in cerebral ischemia models and cerebral vasospasm in subarachnoid hemorrhage models.

Indexed as

Brain IschemiaSubarachnoid HemorrhageVasospasm, IntracranialAnimalsCerebral InfarctionCilostazolLikelihood FunctionsModels, AnimalCilostazolAnimal modelsCerebral ischemiaCilostazolPhosphodiesterase inhibitorsSubarachnoid hemorrhage

Identifiers

PMID36450971
OpenAlexW4310566871

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.